George J. Vergis
Plus aucun poste en cours
Profil
George J.
Vergis served as President & CEO of Neose Technologies, Inc. from 2001 to 2010.
Prior to that, he was Vice President of New Product Development at Knoll Pharmaceutical Co. from 1996 to 2001.
He also served as a Director at Cynvec LLC and a Trustee at Woods Services, Inc. Dr. Vergis holds an MBA from The Trustees of Columbia University in The City of New York, a doctorate from The Pennsylvania State University, and an undergraduate degree from Princeton University.
Anciens postes connus de George J. Vergis
| Sociétés | Poste | Fin |
|---|---|---|
Neose Technologies, Inc.
 Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | President | 08/07/2010 |
| Knoll Pharmaceutical Co. | Corporate Officer/Principal | 01/05/2001 |
Cynvec LLC
 Cynvec LLC Pharmaceuticals: MajorHealth Technology Cynvec LLC develops oncolytic therapeutics for the treatment of cancer. It offers cancer treatment platform to activate the body’s own immune system to safely attack tumors and prevent or slow cancer recurrence. The firm develops CYN-101, a bioengineered Sindbis viral vector vaccine expressing the NY-ESO-1 tumor associated antigen for the treatment of late-stage ovarian cancer; and an immunotherapeutic vaccine for multiple possible cancer targets. The company was founded in 2004 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Woods Services, Inc.
 Woods Services, Inc. Medical/Nursing ServicesHealth Services Woods Services, Inc. provides health, education, housing, workforce, behavioral health and case management services. The company was founded by Mollie Woods in 1913 and is headquartered in Langhorne, PA. | Directeur/Membre du Conseil | - |
Formation de George J. Vergis
| Princeton University | Undergraduate Degree |
| The Pennsylvania State University | Doctorate Degree |
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
Woods Services, Inc.
Woods Services, Inc. Medical/Nursing ServicesHealth Services Woods Services, Inc. provides health, education, housing, workforce, behavioral health and case management services. The company was founded by Mollie Woods in 1913 and is headquartered in Langhorne, PA. | Health Services |
| Knoll Pharmaceutical Co. | |
Cynvec LLC
Cynvec LLC Pharmaceuticals: MajorHealth Technology Cynvec LLC develops oncolytic therapeutics for the treatment of cancer. It offers cancer treatment platform to activate the body’s own immune system to safely attack tumors and prevent or slow cancer recurrence. The firm develops CYN-101, a bioengineered Sindbis viral vector vaccine expressing the NY-ESO-1 tumor associated antigen for the treatment of late-stage ovarian cancer; and an immunotherapeutic vaccine for multiple possible cancer targets. The company was founded in 2004 and is headquartered in New York, NY. | Health Technology |
